An adaptive strategy for assessing regional consistency in multiregional clinical trials

被引:10
|
作者
Chen, Joshua [1 ]
Quan, Hui [2 ]
Gallo, Paul [3 ]
Ouyang, Soo P. [4 ]
Binkowitz, Bruce [1 ]
机构
[1] Merck Res Labs, Rahway, NJ 07026 USA
[2] Sanofi Aventis, Bridgewater, NJ USA
[3] Novartis, E Hanover, NJ USA
[4] Celgene, Summit, NJ USA
关键词
COVARIATE ADJUSTMENT; DESIGN;
D O I
10.1177/1740774512440635
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background Unexpected regional difference in treatment effect has been reported in recent multiregional clinical trials (MRCTs). This may cause difficulty in interpreting results and can have regulatory implications such as marketing approvals and/or product labels in various markets. Careful consideration of consistency across regions and appropriate plans to address potential regional difference are necessary at the design stage. However, assessment of consistency in treatment effect is generally not the primary objective, and therefore, when there is no strong a priori reason to expect a regional difference, a MRCT is not usually designed to address the regional consistency. Unexpected regional finding may arise and increase the risk of ambiguous or controversial results at the end of the study. Purpose To mitigate this risk, we propose an adaptive strategy for regional assessment based upon accumulated blinded data. Methods If review of accumulated blinded data shows unexpectedly severe imbalance in an intrinsic or extrinsic factor, and further assessment indicates that this factor could be a potential effect modifier as supported by biological plausibility or blinded correlation analysis, a stratified regional analysis controlled for this factor may be specified and documented before database lock. Results The proposed adaptive strategy can help with the interpretation of unexpected regional finding. A recent trial is used to illustrate the approach. Limitations Even if the imbalanced factor may appear to explain away the regional difference, establishment of causal effect is usually difficult and requires more involved effort. Conclusions This approach, by prespecifying the stratified analysis, can reduce the risk of post hoc exaggerated emphases across many possible exploratory analyses and provide greater confidence in the validity of the conclusions. If a causal effect can be established that the apparent regional difference is likely caused by this intrinsic or extrinsic factor, this prespecified analysis can also help guide clinical practice.
引用
收藏
页码:330 / 339
页数:10
相关论文
共 50 条
  • [21] Robust estimates of regional treatment effects in multiregional randomized clinical trials with semiparametric logistic model
    Yuan, Ao
    Yang, Chaojie
    Yu, Shilin
    Tan, Ming T.
    [J]. PHARMACEUTICAL STATISTICS, 2022, 21 (01) : 133 - 149
  • [22] DECISION RULES AND ASSOCIATED SAMPLE SIZE PLANNING FOR REGIONAL APPROVAL UTILIZING MULTIREGIONAL CLINICAL TRIALS
    Chen, Xiaoyuan
    Lu, Nelson
    Nair, Rajesh
    Xu, Yunling
    Kang, Cailian
    Huang, Qin
    Li, Ning
    Chen, Hongzhuan
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2012, 22 (05) : 1001 - 1018
  • [23] R Functions for Sample Size and Probability Calculations for Assessing Consistency of Treatment Effects in Multi-Regional Clinical Trials
    Li, Mingyu
    Quan, Hui
    Chen, Joshua
    Tanaka, Yoko
    Ouyang, Peter
    Luo, Xiaolong
    Li, Gang
    [J]. JOURNAL OF STATISTICAL SOFTWARE, 2012, 47 (CS1): : 1 - 10
  • [24] MULTIREGIONAL CLINICAL TRIALS: JAPANESE PERSPECTIVE ON DRUG DEVELOPMENT STRATEGY AND SAMPLE SIZE FOR JAPANESE SUBJECTS
    Ando, Yuki
    Uyama, Yoshiaki
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2012, 22 (05) : 977 - 987
  • [25] Regional efficacy assessment in multiregional clinical development
    Zhou, Yijie
    Cui, Lu
    Yang, Bo
    Zhang, Lanju
    Shen, Frank
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2017, 27 (04) : 673 - 682
  • [26] Practical Recommendations for Regional Consistency Evaluation in Multi-Regional Clinical Trials with Different Endpoints
    Teng, Zhaoyang
    Lin, Jianchang
    Zhang, Bin
    [J]. STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2018, 10 (01): : 50 - 56
  • [27] Bayesian multiregional clinical trials using model averaging
    Bean, Nathan W.
    Ibrahim, Joseph G.
    Psioda, Matthew A.
    [J]. BIOSTATISTICS, 2023, 24 (02) : 262 - 276
  • [28] Multiregional Clinical Trials: An Introduction From an Industry Perspective
    Binkowitz, Bruce
    Ibia, Ekopimo
    [J]. DRUG INFORMATION JOURNAL, 2011, 45 (05): : 569 - 573
  • [29] Hierarchical Generalized Linear Models for Multiregional Clinical Trials
    Park, Junhui
    Kang, Seung-Ho
    [J]. STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2022, 14 (03): : 358 - 367
  • [30] Multiregional Clinical Trials: An Introduction from an Industry Perspective
    Bruce Binkowitz
    Ekopimo Ibia
    [J]. Drug information journal : DIJ / Drug Information Association, 2011, 45 : 569 - 573